07-18-2025
ET-Essential Thrombocythemia
Scenario:
- Essential Thrombocytosis, noted since 2021
- Peripheral Blood+JAK2 V617F mutation
- 07-18-2025 Med Onc Consult: Discussed now formal diagnosis of essential thrombocythemia with JAK2 mutation. He will begin aspirin 81mg daily given low risk disease.
| Field | Code | Rationale |
| Primary Site | C421 | Hematopoietic and Lymphoid Neoplasm Coding Manual |
| Histology | 9962/3 | Hematopoietic and Lymphoid Neoplasm Database |
| Diagnostic Confirmation | 8 | Hematopoietic and Lymphoid Neoplasm Coding Manual SINQ Post https://seer.cancer.gov/seer-inquiry/inquiry-detail/20120015/ |
| Other Treatment | 1 | SEER*Rx Interactive Antineoplastic Drugs Database Code as ‘Other’ therapy for essential thrombocythemia ONLY Hematopoietic and Lymphoid Neoplasm Coding Manual page 26. Collect blood-thinners and/or anti-clotting agents for essential thrombocythemia (9962/3) ONLY |
| Date of First Course Treatment | 07-18-2025 | STORE Date of Other Treatment can be used to code this field |
| Rx Summ – Treatment Status | 1 | Treatment given |
